Eikon Therapeutics, Inc. (EIKN)
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -318.91M |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About EIKN
Eikon Therapeutics is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candi... [Read more]
News
Eikon Therapeutics Launches IPO For Ambitious Oncology Pipeline Development
Eikon Therapeutics, Inc. is pursuing an IPO to fund its oncology pipeline, led by EIK1001 in Phase 2 trials for melanoma and NSCLC. EIKN's initial EIK1001 data show a 60% response rate, limited advers...
Biopharmaceutical firm Eikon Therapeutics files for US IPO
Clinical biopharmaceutical company Eikon Therapeutics on Friday filed for an initial public offering in the United States.
Eikon Therapeutics IPO Registration Document (S-1)
Eikon Therapeutics has filed to go public with an IPO on the NASDAQ
Immuno-responsive cancer biotech Eikon Therapeutics files for an estimated $300 million IPO
Eikon Therapeutics, a Phase 2 biotech developing therapies for immuno-responsive cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering. However, the deal size...